<DOC>
	<DOC>NCT00131118</DOC>
	<brief_summary>This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.</brief_summary>
	<brief_title>Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Have completed the core CZOL446H2202 study Males or females between 117 years of age Deformity or abnormality which would prevent spine bone density from being done Any surgical bonelengthening procedure Any kidney diseases or abnormalities Low calcium or vitamin D levels in the blood Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Osteogenesis Imperfecta, Brittle bone disease, bisphosphonate, children</keyword>
</DOC>